How Oxymetholone Affects Haemoglobin

Oxymetholone raises haemoglobin through multiple erythropoietic mechanisms, reflecting the dual nature of its pharmacology as both a therapeutic anaemia agent and a bodybuilding compound:

1. EPO stimulation: Like all androgens, oxymetholone stimulates renal erythropoietin production. In haematopoietically suppressed states (aplastic anaemia, chemotherapy-induced anaemia), this EPO stimulation can rescue red blood cell production from near-complete suppression.
2. Direct marrow stimulation: Oxymetholone activates androgen receptors on erythroid progenitor cells, promoting proliferation and inhibiting apoptosis of developing red blood cells. This direct bone marrow action is part of why it is effective in aplastic anaemia where the EPO pathway is intact but the marrow is not responding normally.
3. Hepcidin suppression: Oxymetholone suppresses hepcidin, mobilising iron from stores for haemoglobin synthesis in new red blood cells.
4. Iron reutilisation: Oxymetholone may enhance the reutilisation of iron from senescent red blood cells, further supporting haemoglobin synthesis without requiring additional dietary or supplemental iron.

The FDA-approved anaemia treatment context is important: in aplastic anaemia, oxymetholone raised haemoglobin and reduced transfusion dependence. Clinical response rates are 54.1% in non-severe aplastic anaemia and 13.5% in severe aplastic anaemia. At bodybuilding doses, where bone marrow function is normal and haemoglobin is already within the normal range, these same mechanisms drive haemoglobin above the physiological ceiling.

Therapeutic anaemia doses (1-5 mg/kg/day in aplastic anaemia):

• Haemoglobin rises progressively over 3-6 months in responders
• Response rates approximately 54% for non-severe anaemia, 13.5% for severe anaemia
• Responders may achieve haemoglobin normalisation and transfusion independence

Bodybuilding doses (50-100 mg/day in normal individuals):

• Haemoglobin typically rises 2-4 g/dL above baseline within 4-6 weeks
• Users with baseline haemoglobin of 15-16 g/dL commonly reach 17.5-19.5 g/dL
• At 150 mg/day, haemoglobin above 20 g/dL has been reported, with serious thrombotic risk
• The rise is rapid due to high absolute daily dose: oxymetholone is typically used at 50-150 mg/day, a much higher milligram load than most other oral AAS

Co-occurring haematological changes:

• Haematocrit rises in parallel
• RBC count increases
• MCHC may drop as red cell production outpaces haemoglobin synthesis per cell
• Reticulocyte count rises early, preceding haemoglobin elevation by 7-14 days

Baseline: Full CBC including haemoglobin is mandatory before starting oxymetholone. Baseline haemoglobin above 17 g/dL is a contraindication to use given the risk of reaching dangerous levels.

On cycle: Check haemoglobin as part of a full CBC every 4 weeks during use. Oxymetholone's rapid-onset high-dose erythropoiesis can drive haemoglobin above safe thresholds within 3-4 weeks, particularly at 100-150 mg/day.

Paired liver monitoring: Oxymetholone is among the most hepatotoxic oral AAS. ALT, AST, GGT, ALP, and bilirubin must be monitored alongside haemoglobin on every check. The haematological and hepatic risks co-occur and should never be evaluated in isolation.

Post-cycle: Recheck CBC at 2-4 weeks and again at 6-8 weeks after discontinuation. Haemoglobin returns to baseline over 2-3 months as the erythropoietic stimulus is withdrawn and elevated red blood cells complete their natural lifespan.

If haemoglobin is 17.5-18.5 g/dL on oxymetholone:

• Reduce oxymetholone dose or discontinue; the short oral cycle design (4-6 weeks) makes dose reduction mid-cycle feasible
• Ensure excellent hydration to avoid haemoconcentration
• Recheck in 2-3 weeks given the rapid kinetics

If haemoglobin exceeds 18.5 g/dL:

• Discontinue oxymetholone immediately if possible given concurrent hepatotoxicity risk
• Therapeutic phlebotomy: removing 450-500 mL lowers haemoglobin by approximately 1 g/dL
• Recheck in 2-3 weeks

If haemoglobin exceeds 20 g/dL:

• Urgent medical evaluation; this level carries serious thrombotic risk
• Medical phlebotomy as an emergency measure may be warranted
• The combination of extreme haemoglobin, blood viscosity, and oxymetholone-related hepatotoxicity creates a complex clinical picture requiring physician oversight

Cycle design:

• Limit oxymetholone use to 4-6 weeks maximum, which constrains cumulative haemoglobin elevation
• Do not stack oxymetholone with boldenone, trenbolone, or high-dose testosterone: the combined erythropoietic drive creates extreme haemoglobin elevation risk
• Monitor ferritin and iron studies alongside haemoglobin: oxymetholone's intense erythropoietic drive can deplete iron stores rapidly, creating the paradox of high haemoglobin with falling ferritin and rising RDW